BioNTech Investor Day Presentation Deck
mRNA technology | Trans-amplifying RNA could potentially
be a vaccine strategy to induce potent immunity
Trans-amplifying mRNA structure
Cap UTR Replicase
VUTR Antigen
Cap
Cap VUTR Antigen
Cap VUTR Antigen
Cap
VUTR Antigen
Trans-amplifying mRNA mechanism
Positive-sense
replicase
Replicase
(non-self amplifying)
Transgene
UTR A30-L-A70
VUTR A30-L-A70
VUTR A30-L-A70
VUTR A30-L-A70
VUTR A30-L-A70
Internal data.
Positive-sense
transgene
no RNA
Cytoplasm
HET-ARINA
mRNA
wwwwwwwww
HEL-WINA
G24+
EFPA
GFP
Negative-sense
transgene
taRNA
HER-ENTRAMenin.
OPPA
Enhanced translation
by ribosomes
Vaccine antigen
(enhanced immunogenicity)
mRNA
(transgene)
Immunogenicity model
taRNA: SFV
Formulation: PBS
Route: i.d.
VNT-titer/50μl
prime
Day 1
1000
100
10
1
boost
Day 21
O
buffer 20 µg
mRNA
O
O
O
6.25
+*
Day 55 titer
O
Multi-platform engine
D
111
D
Virus neutralisation
018
1.25 0.25
trans-replicon (x µg)
+ 20 µg replicase
Comparable immunogenicity with approximately 400-fold lower doses of taRNA compared to mRNA
၅၀၀
0.05
BIONTECH
32View entire presentation